
## Board of Pharmacy Summary of Budget Recommendations - House

Page VIII-40 Allison Vordenbaumen Benz, R.Ph., M.S., Executive Director Daniela Fragoso, LBB Analyst


	2020-21	2022-23	Biennial	Biennial
Method of Financing	Base	Recommended	Change (\$)	Change (%)
General Revenue Funds	\$18,163,123	\$18,258,866	\$95,743	0.5%
GR Dedicated Funds	\$0	\$0	\$0	0.0%
Total GR-Related Funds	\$18,163,123	\$18,258,866	\$9 <i>5,</i> 7 <i>4</i> 3	0.5%
Federal Funds	<b>\$</b> 0	<b>\$</b> 0	\$0	0.0%
Other	\$2,028,030	\$2,028,030	\$0	0.0%
All Funds	\$20,191,153	\$20,286,896	\$95,743	0.5%

	FY 2021	FY 2023	Biennial	Percent
	Budgeted	Recommended	Change	Change
FTEs	110.0	110.0	0.0	0.0%

#### **Historical Funding Levels (Millions)**



#### Historical Full-Time-Equivalent Employees (FTEs)



The bill pattern for this agency (2022-23 Recommended) represents an estimated 100.0% of the agency's estimated total available funds for the 2022-23 biennium.

# Board of Pharmacy Summary of Funding Changes and Recommendations - House

Funding Changes and Recommendations for the 2022-23 Biennium compared to the 2020-21 Base Spending Level (in millions)		General Revenue	GR-Dedicated	Federal Funds	Other Funds	All Funds	Strategy in Appendix A
SIGNIFICANT Funding Changes and Recommendations (each issue is explained in Section 3 and additional details are provided in Appendix A):							
A)	Decrease of one-time expenses for: 1) vehicle replacements, 2) start-up costs for 5.0 new FTEs, 3) Senate Bill 683 PMP database modifications, and 4) House Bill 3284 start-up costs for 6.0 FTEs for the Prescription Monitoring Program.	(\$0.2)	\$0.0	\$0.0	\$0.0	(\$0.2)	B.1.1, B.1.3
B)	Increase to cover cost increases for Health Professions Council services.	\$0.2	\$0.0	\$0.0	\$0.0	\$0.2	B.1.1
C)	Increase to cover contract cost increases for peer assistance program.	\$0.1	\$0.0	\$0.0	\$0.0	\$0.1	B.1.2
T	OTAL SIGNIFICANT & OTHER Funding Changes and Recommendations (in millions)	\$0.1	\$0.0	\$0.0	\$0.0	\$0.1	As Listed
	SIGNIFICANT & OTHER Funding Increases	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	As Listed
	SIGNIFICANT & OTHER Funding Decreases	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	As Listed

NOTE: Totals may not sum due to rounding.

### Board of Pharmacy Selected Fiscal and Policy Issues - House

- 1. **One-Time Expenses.** The Texas State Board of Pharmacy (TSBP) was appropriated \$240,780 in General Revenue Funds in the 2020–21 biennium related to one-time expenses for the following items. Recommendations include a corresponding decrease.
  - Vehicle Replacements \$66,000
  - Start-up costs for 5.0 new full-time equivalent (FTE) positions \$81,120
  - Senate Bill 683 Prescription Monitoring Program database modifications \$65,000
  - House Bill 3284 Prescription Monitoring Program 6.0 FTE start-up costs \$28,660
- 2. **Continue Enhanced Features in the Prescription Monitoring Program.** TSBP manages the Prescription Monitoring Program (PMP), which collects and monitors prescription data for controlled substances for prescribers, pharmacies, and patients through an online database. All pharmacists and prescribers, with the exception of veterinarians, are required to check patient history in the PMP database before prescribing or dispensing certain controlled substances. The agencies listed in the table below contribute to the funding of the PMP. Recommendations include \$3.0 million in General Revenue Funds for Strategy B.1.3, Prescription Monitoring Program.

Senate Bill 500, Eighty-sixth Legislature, 2019, the supplemental appropriations bill, increased funding to TSBP for the Prescription Monitoring Program (PMP) by \$6.1 million in General Revenue Funds for upgrades to the PMP database so that it could support certain enhanced features. This funding also covered the cost of the software subscriptions for Statewide Integration (\$4.2 million), NarxCare (\$0.8 million), and Clinical Alerts (\$0.04 million) for fiscal years 2020 and 2021. The agency is requesting an additional \$5.0 million in General Revenue Funds in the 2022-23 biennium to maintain these software subscriptions so that prescribers can continue using the enhanced features. These subscription costs would be an on-going cost. Recommendations do not include funding for this exceptional item request.

Because the PMP-contributing agencies are required to collect enough revenue to cover their appropriations and other direct and indirect costs, it is possible that an increased appropriation for PMP could result in subsequent increases to license fees. The agency reports that they have polled some of the prescribers that use PMP and find great support for the enhanced features provided by these software subscriptions. The table below is an informational listing of fee revenue each agency would need to supply for the purpose of paying for the increased funding for the PMP.

Participating Agency	2022-23 Recommendations	2022-23 Recs + PMP Exceptional Item	Difference
Texas Medical Board	\$1,397,094	\$3,690,976	\$2,293,883
Optometry Board	\$89,046	\$235,249	\$146,204
Texas State Board of Dental Examiners	\$260,996	\$689,523	\$428,528
Texas State Board of Nursing	\$313,195	\$827,428	\$514,233
Board of Veterinary Medical Examiners	\$300,913	\$794,980	\$494,067
Texas Department of Licensing and Regulation	\$15,353	\$40,560	\$25,208
Board of Pharmacy	\$693,941	\$1,833,320	\$1,139,379
Total	\$3,070,536	\$8,112,036	\$5,041,500

#### Section 3

- 3. **Health Professions Council Cost Increases.** Recommendations include an increase of \$234,127 in General Revenue Funds for increased costs associated with the shared regulatory database used by TSBP via the Health Professions Council.
- 4. **Peer Assistance Program.** TSBP contracts with the Professional Recovery Network to provide a peer assistance program for licensees with impairments, such as chemical abuse or dependency and certain mental health diagnoses, to receive treatment and monitoring before returning to work. The agency's Strategy B.1.2, Peer Assistance, was exempt from the five percent reduction under the behavioral health services exemption. Recommendations include an increase of \$102,396 in General Revenue Funds to cover the increased contract cost in overhead for salary and benefits and non-salary expenses such as taxes and printing, outside evaluations and referrals, and staff expenses for increased training. Recommendations include a total of \$588,405 in General Revenue Funds for the peer assistance program for the biennium. The agency reports the peer assistance program served 131 participants in fiscal year 2020.

#### Board of Pharmacy Rider Highlights - House

#### **Modification of Existing Riders**

2. **Controlled Substance Forfeiture Program.** This rider authorizes the appropriation of any proceeds from the sale of forfeited property related to the agency's participation in the seizure of controlled substances or other contraband to the agency to be used for enforcement purposes and provides unexpended balance transfer authority between biennia and between years in the biennium. Recommendations modify this rider to remove the reference to the amount appropriated for the purpose of the Controlled Substance Forfeiture Program because the agency has little control over how many enforcement cases become involved with the program.

#### **Deleted Riders**

4. **Lump Sum Retiree Payout.** Recommendations delete this rider which required the agency to lapse certain funds if the funds were not used for retirement payouts due at the time of agency employees' retirement. This change would not impact the agency's ability to continue to make lump sum payments as necessary.

## Board of Pharmacy Items Not Included in Recommendations - House

		2022-23 Biennial Total					
		GR & GR-D All Funds FTEs		Information Technology Involved?  Contracting Involved?		Estimated Continued Cost 2024-25	
Agency E	exceptional Items Not Included (in agency priority order)						
1) Cc	apitol Complex Move: Data Center Services and Microsoft Azure Services for cloud storage	\$45,000	\$45,000	0.0	Yes	No	\$72,000
2) Cc	apitol Complex Move: Firewalls, switches, and networking equipment	\$25,000	\$25,000	0.0	Yes	No	\$0
3) Cc	apitol Complex Move: Office furniture	\$187 <b>,</b> 977	\$187,977	0.0	No	Yes	\$0
4) Cc	apitol Complex Move: Visitor Management System	\$6,000	\$6,000	0.0	Yes	No	\$6,000
5) Co	apitol Complex Move: Live Streaming/Audiovisual Equipment and Software	\$10,000	\$10,000	0.0	Yes	No	\$C
6) Cc	apitol Complex Move: CaptionMaker for Telestream	\$1 <i>7,</i> 550	\$1 <i>7,</i> 550	0.0	Yes	No	\$4,050
7) Re	cords Analyst/Certified Records Manager (Program Specialist IV)	\$1 <i>5</i> 8, <i>7</i> 82	\$1 <i>5</i> 8, <i>7</i> 82	1.0	No	No	\$1 <i>5</i> 1 <b>,</b> 500
8) Ac	countant IV	\$128,232	\$128,232	1.0	No	No	\$111,100
9) Me	erit Increases for Staff	\$497,162	\$497,162	0.0	No	No	\$665,678
• , , , , , , ,	escription Monitoring Program Software Subscriptions	\$5,041,500	\$5,041,500	0.0	Yes	No	\$5,041,500

### Board of Pharmacy Appendices - House

	Table of Contents					
Appendix	Appendix Title	Page				
A	Funding Changes and Recommendations by Strategy	8				
В	Summary of Federal Funds	*				
С	FTE Highlights	9				

<sup>\*</sup> Appendix is not included - no significant information to report

Board of Pharmacy
Funding Changes and Recommendations by Strategy - House -- ALL FUNDS

2020-21 Base	2022-23 Recommended	Biennial Chanae	% Change	Comments (Optional)
2400		ege	- Ciranigo	сенноше (ориена,
\$1,992,265	\$1,992,264	(\$1)	(0.0%)	
\$502,212	\$502,212	\$0	0.0%	
\$2,494,477	\$2,494,476	(\$1)	(0.0%)	
\$10,308,612	\$10,395,619	\$87,007	0.8%	
\$486,009	\$588,405	\$102,396	21.1%	
\$5,174,336	\$4,976,876	(\$197,460)	(3.8%)	
\$15,968,957	\$15,960,900	(\$8,057)	(0.1%)	
\$249,973	\$259,974	\$10,001	4.0%	
\$1,477,746	\$1,571,546	\$93,800	6.3%	
\$1,727,719	\$1,831,520	\$103,801	6.0%	
\$20,191,153	\$20,286,896	\$95,743	0.5%	
	\$1,992,265 \$502,212 \$2,494,477 \$10,308,612 \$486,009 \$5,174,336 \$15,968,957 \$249,973 \$1,477,746 \$1,727,719	\$1,992,265 \$1,992,264 \$502,212 \$502,212 \$2,494,477 \$2,494,476  \$10,308,612 \$10,395,619 \$486,009 \$588,405 \$5,174,336 \$4,976,876 \$15,968,957 \$15,960,900  \$249,973 \$259,974 \$1,477,746 \$1,571,546 \$1,727,719 \$1,831,520	Base         Recommended         Change           \$1,992,265         \$1,992,264         (\$1)           \$502,212         \$502,212         \$0           \$2,494,477         \$2,494,476         (\$1)           \$10,308,612         \$10,395,619         \$87,007           \$486,009         \$588,405         \$102,396           \$5,174,336         \$4,976,876         (\$197,460)           \$15,968,957         \$15,960,900         (\$8,057)           \$249,973         \$259,974         \$10,001           \$1,477,746         \$1,571,546         \$93,800           \$1,727,719         \$1,831,520         \$103,801	Base         Recommended         Change         Change           \$1,992,265         \$1,992,264         (\$1)         (0.0%)           \$502,212         \$502,212         \$0         0.0%           \$2,494,477         \$2,494,476         (\$1)         (0.0%)           \$10,308,612         \$10,395,619         \$87,007         0.8%           \$486,009         \$588,405         \$102,396         21.1%           \$5,174,336         \$4,976,876         (\$197,460)         (3.8%)           \$15,968,957         \$15,960,900         (\$8,057)         (0.1%)           \$249,973         \$259,974         \$10,001         4.0%           \$1,477,746         \$1,571,546         \$93,800         6.3%           \$1,727,719         \$1,831,520         \$103,801         6.0%

### Board of Pharmacy FTE Highlights - House

Full-Time-Equivalent Positions	Expended 2019	Estimated 2020	Budgeted 2021	Recommended 2022	Recommended 2023
Сар	98.0	110.0	110.0	110.0	110.0
Actual/Budgeted	92.8	96.1	110.0	NA	NA
Schedule of Exempt Positions (Cap)					
Executive Director, Group 4	\$132,490	\$141,510	\$141,510	\$141,510	\$141,510

#### Notes:

a) The State Auditor's Office Report, Executive Compensation at State Agencies (Report 20-706, August 2020), indicates a market average salary of \$151,470 for the Executive Director position at the Board of Pharmacy. The agency is not requesting any changes to its exempt position.